OrbusNeich Medical Group Holdings Limited reported that the authorized share capital remained unchanged at 1,200,000,000 ordinary shares (USD 0.0005 par value each), totaling USD 600,000. No increase or decrease was recorded during February 2026.

The total number of issued shares remained at 827,968,337, with zero treasury shares. The public float requirement, set at 25% of the total issued shares excluding treasury shares, was confirmed to be met.

During the reporting period, certain share options lapsed under both the Pre-IPO and Post-IPO Share Option Schemes. Under the Pre-IPO Share Option Scheme, 48,000 options lapsed, leaving 7,633,000 outstanding. Under the Post-IPO Share Option Scheme, 20,000 options lapsed, leaving 4,347,000 outstanding. No new shares were issued, and no treasury shares were transferred during the month.